Perceptive Inc.

Every stage of early drug development brings a different question. Is the target accessible? Is the molecule reaching it? Which candidate should advance? What data are needed to support IND submission? Quantitative imaging can help answer these questions with measurable biological evidence. Our latest blog explores how PET, SPECT, MRI and optical imaging can support better-informed decisions from discovery through IND-enabling studies. 📖 Read the blog and download the Imaging Decision Roadmap: Quantitative Imaging: https://lnkd.in/gvGJSNYg #QuantitativeImaging #DrugDevelopment #PreclinicalImaging #TranslationalResearch

How do you demonstrate disease modification in Parkinson's disease (PD) when measuring progression remains so complex? As sponsors pursue therapies aimed at slowing or altering disease progression, imaging biomarkers and innovative trial designs are becoming increasingly important to development strategies. Join leading experts from academia and industry as they explore:  • The biology behind PD progression  • Advances in PD imaging and biomarker development • Strategies for assessing and monitoring PD • What a biomarker-driven future could mean for clinical trials 📅 September 15 | 11:00 AM ET Reserve your spot: https://lnkd.in/dkxxSW-P Duygu Tosun-Turgut Elif Sikoglu David Russell

As PSMA-targeted therapies continue to advance, imaging teams are under increasing pressure to generate high-quality quantitative data quickly, consistently, and at scale. The challenge is managing growing data volumes while maintaining the scientific rigor and expert oversight that sponsors depend on. Perceptive scientists recently presented research on an automated multi-anatomy lesion segmentation and classification approach to support PSMA-PET analysis. The workflow uses machine learning to help identify lesions, separate adjacent lesions, classify anatomy, and accelerate lesion-level quantitative assessment, enabling experts to focus more of their time on interpretation and quality review. The results were promising: ✅ Strong agreement with expert manual segmentations ✅ Greater reproducibility across datasets ✅ Reduced inter-reader variability ✅ More than 50% reduction in reader time per scan As the volume and complexity of PSMA-PET studies continue to grow, thoughtfully applied automation may help sponsors improve scalability while maintaining confidence in the quality of their data. Access the poster: https://lnkd.in/eCdPvVzR #SNMMI #PSMAPET #ProstateCancer #ClinicalTrials #MedicalImaging #ArtificialIntelligence #NuclearMedicine

Radioligand therapy combinations have the potential to improve therapeutic response, but selecting the right combination, model and dosing strategy is critical. Now available on demand, our webinar featuring Julian Goggi, PhD, explores the science behind RLT combination strategies and the translational tools needed to evaluate them effectively. Learn about mechanism-based pairing strategies, preclinical model selection, quantitative imaging, dosimetry and key considerations for balancing efficacy and toxicity. ▶️ Watch the webinar on demand: https://lnkd.in/g_AupPY6 #RadioligandTherapy #RLT #Oncology #PreclinicalResearch #NuclearMedicine

In just a few weeks, the Perceptive Discovery team will be heading to #WMIC2026 in Salt Lake City!   Meet Lisa Wells, PhD, Charles Zamilpa, PhD, and Desmond Jacob, MS to discuss how quantitative molecular imaging can provide earlier, more meaningful insights into target engagement, biodistribution, pharmacology, and therapeutic response throughout drug development. 📍 Salt Lake City, UT | September 8–11 Attending WMIC? Schedule a meeting with our team: https://lnkd.in/ev-GEYjH #WMIC2026 #MolecularImaging #PreclinicalImaging #TranslationalResearch #DrugDevelopment

In quantitative imaging, how you analyze the data can be just as important as how you acquire it. Segmentation, quantification methods, decay correction and dosimetry assumptions can all influence the conclusions drawn from a preclinical imaging study. On August 26, join Keryn Gresco (Palmer), Director of Image Analysis and Software Platforms at Perceptive Discovery, for a technical discussion on the analytical methods behind reliable, reproducible imaging data. Keryn will explore segmentation, quantification, quality control and dosimetry, and how rigorous analysis can strengthen the endpoints used to make critical drug development decisions. 📅 August 26 | 10:00 AM EDT Register here: https://lnkd.in/g6Ms-ear #QuantitativeImaging #PreclinicalImaging #Dosimetry #Radiopharmaceuticals #DrugDevelopment

Facing an aggressive timeline, the sponsor of a large Phase 3 Alzheimer's trial needed scalable imaging services to meet their accelerated enrollment goals. With 390 sites onboarded in under three months and PET eligibility reviews delivered within 2-4 days, Perceptive’s operational precision helped the sponsor keep the study on track and ultimately achieve FDA approval for their breakthrough Alzheimer’s disease therapy. Read the case study: https://lnkd.in/ervcMu5B

A warm welcome to our newest apprentice and graduate hires in India! Investing in early talent is investing in the future, and we are excited to be part of their career journey as they learn, grow, and make a difference at Perceptive. If you're looking for new career opportunities, visit our Careers page and explore how you can be part of our journey too. https://lnkd.in/eN33CXJB

FAP-targeted imaging and theranostics are moving rapidly from scientific promise to clinical reality. But as these programs progress to late-stage clinical development, sponsors face an important question: Is the broader imaging ecosystem prepared to support widespread adoption? In this on-demand roundtable discussion, experts from industry and academia explore what must happen across the clinical imaging ecosystem to support the continued advancement of FAP imaging and theranostics. The discussion examines: • Healthcare system readiness • Global imaging site network preparedness • Reader training and standardization • Considerations for scaling FAP programs across regions and studies • Opportunities and challenges as the field moves toward broader clinical adoption The conversation provides practical insights for sponsors, clinical development teams, nuclear medicine professionals, and imaging experts looking to navigate the evolving FAP landscape and prepare for what's next. 🎥 Watch the webinar recording: https://lnkd.in/eFT3Ztkx #Theranostics #FAP #Radiopharmaceuticals #MolecularImaging #NuclearMedicine #Oncology #ClinicalTrials #DrugDevelopment #ClinicalResearch #MedicalImaging #PrecisionMedicine

Can quantitative image quality metrics help identify off-target signal and image noise in amyloid PET scans? In this AAIC 2026 poster, Perceptive Imaging researchers explored quantitative approaches for assessing off-target signal and image noise in amyloid PET imaging from the multicenter Alzheimer’s Disease Neuroimaging Initiative (ADNI) study and evaluated how these measures relate to visual quality control assessments. The analysis found meaningful associations between quantitative metrics and qualitative visual ratings, offering potentially earlier detection of image quality issues and tracer-specific imaging characteristics. 📄 Download the poster to learn: ✅ How quantitative image quality measures aligned with expert visual assessments ✅ What the findings revealed about noise levels and extracerebral binding in amyloid PET scans and how these metrics differed between tracers ✅ How quantitative analyses may help deepen our understanding of image quality characteristics in large PET imaging datasets Access the poster here: https://lnkd.in/e-2g4GCC David Cash Joseph Petrulli Elif Sikoglu Alex Whittington Samuel Lockhart #AAIC2026 #AlzheimersDisease #AmyloidPET #Neuroimaging #ClinicalResearch #MedicalImaging #ImagingScience #PerceptiveImaging